Fox Chase Cancer Center News

MBCure, a nonprofit focused on metastatic breast cancer (MBC) research, awareness, education, and access efforts, is launching the MBCure Research Consortium with three of the world’s leading cancer institutions: Fox Chase Cancer Center, Penn Medicine’s Abramson Cancer Center, and Memorial Sloan Kettering Cancer Center (MSK).

Sanjeevani Arora, PhD, Assistant Professor in the Cancer Prevention and Control Research Program and a member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, was recently recognized by the Journal of the American Medical Association (JAMA) Network Open for significant contributions in her role as a reviewer.

A new method of assessing workloads for clinical researchers at Fox Chase Cancer Center has proven effective in mitigating workload imbalances and improving phase 1 clinical programs. The findings of this project were presented at the Association of American Cancer Institutes’ (AACI) Clinical Research Innovation (CRI) Annual Meeting.

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become resistant to therapy. New research co-headed by a Fox Chase Cancer Center scientist helps explain why — and offers three strategies for making treatment more effective.

Jeffrey Farma, MD, FACS, Chair and Professor in the Department of Surgery, was honored today for his appointment to the Paul Grotzinger and Wilbur Raab Chair in Surgical Oncology at Fox Chase Cancer Center.

Fox Chase Cancer Center clinical research nurse Colbi Carr, BSN, RN, recently became a member of the ECOG-ACRIN Research Group’s Oncology Nursing Committee.

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role in colon cancer. Researchers also showed how this mutation could be targeted therapeutically.

A pilot program developed to educate healthcare providers about patient chemosensory dysfunction significantly improved providers’ knowledge and confidence in providing support to patients, according to a recent publication on the program from clinicians and researchers at Fox Chase Cancer Center.